Why Antibacterial Minor Groove Binders Are a Good Thing

Colin J. Suckling, Iain Hunter, Abedawn I. Khalaf, Fraser Scott, Nicholas Tucker, Leena Niemenen, Kimon Lemonidis

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

The challenge of antimicrobial resistance is well understood and extensive research is underway worldwide to find effective, new antibacterial agents that will be less susceptible to the emergence of resistance than those of previous generations. The challenge of combining potency with resilience is unlikely to be met using the standard medicinal chemistry paradigm of single drug, single target, single effect. Our approach using specially designed minor groove binders for DNA (Strathclyde MGBs), whilst formally attacking a single molecular target, in practice disrupts many biological processes such that the emergence of resistance can be expected to be low. The first example of this approach to reach the clinic, MGB-BP-3, is highly effective against Gram positive bacteria and has been successfully taken through a Phase 1 clinical trial for the treatment of Clostridium difficile infections by our development partner, MGB Biopharma. Mechanism of action studies with S. aureus as the target organism have provided evidence consistent with the expectation. RNAseq experiments have shown that there are substantial changes in gene expression, some upregulated and others downregulated, such that the bacterium faces multiple metabolic challenges to its survival. In particular processes associated with cell wall integrity and energy production are affected, the latter being consistent with the steep dose response kill curve observed with this type of drug. Moreover attempts to generate resistant strains have failed. Taken together, these properties identify Strathclyde minor groove binders as significant new compounds in the fight against antibacterial resistance.
LanguageEnglish
Title of host publication3rd International Electronic Conference on Medicinal Chemistry
DOIs
Publication statusPublished - 1 Nov 2017
Event3rd International Electronic Conference on Medicinal Chemistry -
Duration: 1 Nov 201730 Nov 2017
https://ecmc-3.sciforum.net/ (Link to Conference Website)

Conference

Conference3rd International Electronic Conference on Medicinal Chemistry
Period1/11/1730/11/17
OtherWebinar
Internet address

Fingerprint

Clostridium Infections
Biological Phenomena
Clinical Trials, Phase I
Clostridium difficile
Pharmaceutical Chemistry
Gram-Positive Bacteria
Pharmaceutical Preparations
Cell Wall
Down-Regulation
Anti-Bacterial Agents
Bacteria
Gene Expression
DNA
Research

Cite this

Suckling, C. J., Hunter, I., Khalaf, A. I., Scott, F., Tucker, N., Niemenen, L., & Lemonidis, K. (2017). Why Antibacterial Minor Groove Binders Are a Good Thing. In 3rd International Electronic Conference on Medicinal Chemistry https://doi.org/10.3390/ecmc-3-04651
Suckling, Colin J. ; Hunter, Iain ; Khalaf, Abedawn I. ; Scott, Fraser ; Tucker, Nicholas ; Niemenen, Leena ; Lemonidis, Kimon. / Why Antibacterial Minor Groove Binders Are a Good Thing. 3rd International Electronic Conference on Medicinal Chemistry. 2017.
@inproceedings{d2750907535245f8a99aa2b9a6d592d4,
title = "Why Antibacterial Minor Groove Binders Are a Good Thing",
abstract = "The challenge of antimicrobial resistance is well understood and extensive research is underway worldwide to find effective, new antibacterial agents that will be less susceptible to the emergence of resistance than those of previous generations. The challenge of combining potency with resilience is unlikely to be met using the standard medicinal chemistry paradigm of single drug, single target, single effect. Our approach using specially designed minor groove binders for DNA (Strathclyde MGBs), whilst formally attacking a single molecular target, in practice disrupts many biological processes such that the emergence of resistance can be expected to be low. The first example of this approach to reach the clinic, MGB-BP-3, is highly effective against Gram positive bacteria and has been successfully taken through a Phase 1 clinical trial for the treatment of Clostridium difficile infections by our development partner, MGB Biopharma. Mechanism of action studies with S. aureus as the target organism have provided evidence consistent with the expectation. RNAseq experiments have shown that there are substantial changes in gene expression, some upregulated and others downregulated, such that the bacterium faces multiple metabolic challenges to its survival. In particular processes associated with cell wall integrity and energy production are affected, the latter being consistent with the steep dose response kill curve observed with this type of drug. Moreover attempts to generate resistant strains have failed. Taken together, these properties identify Strathclyde minor groove binders as significant new compounds in the fight against antibacterial resistance.",
author = "Suckling, {Colin J.} and Iain Hunter and Khalaf, {Abedawn I.} and Fraser Scott and Nicholas Tucker and Leena Niemenen and Kimon Lemonidis",
year = "2017",
month = "11",
day = "1",
doi = "10.3390/ecmc-3-04651",
language = "English",
booktitle = "3rd International Electronic Conference on Medicinal Chemistry",

}

Suckling, CJ, Hunter, I, Khalaf, AI, Scott, F, Tucker, N, Niemenen, L & Lemonidis, K 2017, Why Antibacterial Minor Groove Binders Are a Good Thing. in 3rd International Electronic Conference on Medicinal Chemistry. 3rd International Electronic Conference on Medicinal Chemistry, 1/11/17. https://doi.org/10.3390/ecmc-3-04651

Why Antibacterial Minor Groove Binders Are a Good Thing. / Suckling, Colin J.; Hunter, Iain; Khalaf, Abedawn I.; Scott, Fraser; Tucker, Nicholas; Niemenen, Leena; Lemonidis, Kimon.

3rd International Electronic Conference on Medicinal Chemistry. 2017.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

TY - GEN

T1 - Why Antibacterial Minor Groove Binders Are a Good Thing

AU - Suckling, Colin J.

AU - Hunter, Iain

AU - Khalaf, Abedawn I.

AU - Scott, Fraser

AU - Tucker, Nicholas

AU - Niemenen, Leena

AU - Lemonidis, Kimon

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The challenge of antimicrobial resistance is well understood and extensive research is underway worldwide to find effective, new antibacterial agents that will be less susceptible to the emergence of resistance than those of previous generations. The challenge of combining potency with resilience is unlikely to be met using the standard medicinal chemistry paradigm of single drug, single target, single effect. Our approach using specially designed minor groove binders for DNA (Strathclyde MGBs), whilst formally attacking a single molecular target, in practice disrupts many biological processes such that the emergence of resistance can be expected to be low. The first example of this approach to reach the clinic, MGB-BP-3, is highly effective against Gram positive bacteria and has been successfully taken through a Phase 1 clinical trial for the treatment of Clostridium difficile infections by our development partner, MGB Biopharma. Mechanism of action studies with S. aureus as the target organism have provided evidence consistent with the expectation. RNAseq experiments have shown that there are substantial changes in gene expression, some upregulated and others downregulated, such that the bacterium faces multiple metabolic challenges to its survival. In particular processes associated with cell wall integrity and energy production are affected, the latter being consistent with the steep dose response kill curve observed with this type of drug. Moreover attempts to generate resistant strains have failed. Taken together, these properties identify Strathclyde minor groove binders as significant new compounds in the fight against antibacterial resistance.

AB - The challenge of antimicrobial resistance is well understood and extensive research is underway worldwide to find effective, new antibacterial agents that will be less susceptible to the emergence of resistance than those of previous generations. The challenge of combining potency with resilience is unlikely to be met using the standard medicinal chemistry paradigm of single drug, single target, single effect. Our approach using specially designed minor groove binders for DNA (Strathclyde MGBs), whilst formally attacking a single molecular target, in practice disrupts many biological processes such that the emergence of resistance can be expected to be low. The first example of this approach to reach the clinic, MGB-BP-3, is highly effective against Gram positive bacteria and has been successfully taken through a Phase 1 clinical trial for the treatment of Clostridium difficile infections by our development partner, MGB Biopharma. Mechanism of action studies with S. aureus as the target organism have provided evidence consistent with the expectation. RNAseq experiments have shown that there are substantial changes in gene expression, some upregulated and others downregulated, such that the bacterium faces multiple metabolic challenges to its survival. In particular processes associated with cell wall integrity and energy production are affected, the latter being consistent with the steep dose response kill curve observed with this type of drug. Moreover attempts to generate resistant strains have failed. Taken together, these properties identify Strathclyde minor groove binders as significant new compounds in the fight against antibacterial resistance.

U2 - 10.3390/ecmc-3-04651

DO - 10.3390/ecmc-3-04651

M3 - Conference contribution

BT - 3rd International Electronic Conference on Medicinal Chemistry

ER -

Suckling CJ, Hunter I, Khalaf AI, Scott F, Tucker N, Niemenen L et al. Why Antibacterial Minor Groove Binders Are a Good Thing. In 3rd International Electronic Conference on Medicinal Chemistry. 2017 https://doi.org/10.3390/ecmc-3-04651